Disposition of orally administered atuliflapon, a novel 5-lipoxygenase-activating protein inhibitor in healthy participants.
Li XQ, Lindmark B, Amilon C, Samuelsson K, Weidolf L, Nelander K, Knöchel J, Heijer M, Bragg RA, Gränfors M, Lindstedt EL, Sidhu S, Garkaviy P, Ericsson H.
Li XQ, et al. Among authors: sidhu s.
Pharmacol Res Perspect. 2024 Oct;12(5):e70029. doi: 10.1002/prp2.70029.
Pharmacol Res Perspect. 2024.
PMID: 39400479
Free PMC article.